These small molecules consist of two halves - one that binds to tumor cells and the other that activates a key receptor, CD16, on the natural killer cell surface. When the natural killer cell encounters this biologic bound to the tumor cell, it knows to attack the tumor cell. 

Like, BiKEs these small molecules have a tumor-binding and CD16-binding parts, but also have a cytokine to activate the natural killer cells and enhance the survival, cell division and movement leading to a more effective therapy.

We are currently testing new drug formats and delivery mechanisms.